Effects of Multimodal Analgesia on Serum MCP-1, BDNF, and MiRNA-124 in Hysterectomy Surgery

Study Overview
=================
Brief Summary
-----------------
The inflammatory process is the main mechanism in the occurrence of acute postoperative pain. It is also the main risk for the development of acute pain into persistent pain. Inflammation occurs in the process of peripheral sensitization and central sensitization with various inflammatory mediators. Postoperatively, there will be proliferation and activation of microglia and astrocytes which will then activate inflammatory receptors and signaling cascades of neurotransmitters, cytokines, and chemokines. There has been a lot of clinical research evidence that multimodal analgesia can adequately treat acute pain and can prevent the development of acute postoperative pain into persistent pain and chronic postoperative pain, but the molecular mechanisms are not fully understood.

Official Title
-----------------
Effects of Multimodal Analgesia on Monocyte Chemoattractant Protein-1, Brain-derived Neurotrophic Factor, and RNA-124 Micro to Acute Pain in Patients Who Underwent Hysterectomy

Conditions
-----------------
Inflammation, Inflammatory Response, Acute Pain, Chronic Pain

Intervention / Treatment
-----------------
* Drug: Multimodal analgesia
* Drug: Conventional intravenous analgesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Scheduled for elective hysterectomy American Society of Anesthesiologists (ASA) physical status 1 to 3 Exclusion Criteria: allergy to studied drugs history of chronic pain history of hepatitis, depression, peptic ulcer, or acute myocardial infarction receive intraoperative massive blood transfusion prolonged coagulation body mass index >35 kg/m2 patients with neurological deficits taking anti-platelet medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hysterectomy<br>Patients who undergo surgical hysterectomy that fits inclusion and exclusion criteria | Drug: Multimodal analgesia<br>* Multimodal analgesia includes the combination of: morphine given by PCA (patient-controlled analgesia) at 1 mg/dose bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery<br>* Other names: Group M;Drug: Conventional intravenous analgesia<br>* Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose<br>* Other names: Group C;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Preoperative MCP-1 | serum level of MCP-1 | 1-hour before surgery | 
| Preoperative BDNF | serum level of BDNF | 1-hour before surgery | 
| Preoperative MiRNA-124 | serum level of MiRNA-124 | 1-hour before surgery | 
| Postoperative MCP-1 | serum level of MCP-1 | 48-hours after surgery | 
| Postoperative BDNF | serum level of BDNF | 48-hours after surgery | 
| Postoperative MiRNA-124 | serum level of MiRNA-124 | 48-hours after surgery |